CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Genelux CORP (GNLX) / olvimulogene nanivacirepvec
Forward catalyst · GNLX

olvimulogene nanivacirepvec

Sponsor Genelux CORP · listed as GNLX

READOUT Phase 3 Confidence: medium Source: clinicaltrials

olvimulogene nanivacirepvec is a drug asset sponsored by Genelux CORP, listed as GNLX. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 2026 (month precision, medium confidence), tied to trial NCT05281471. That trial is in Phase 3 and currently recruiting, studying Platinum-resistant Ovarian Cancer.

Next catalyst

Event typeREADOUT
Expected date2026-12-31
As disclosedDec 2026
Date precisionmonth
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT05281471
PhasePHASE3
StatusRECRUITING
Lead sponsorGenelux Corporation
Listed asGNLX
Condition(s)Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; High-grade Serous Ovarian Cancer; Endom…
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.

Get the full dataset — $499 →   More GNLX catalysts

Related catalysts and sponsor